Trials / Completed
CompletedNCT00640926
Safety and Efficacy Study of Oxazolidinone to Treat Pneumonia
A Phase 2, Multicenter, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of RX-1741 in the Treatment of Adult Patients With Mild to Moderate Severity of Community-Acquired Pneumonia (CAP)
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 158 (actual)
- Sponsor
- Melinta Therapeutics, Inc. · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine whether RX-1741, an oxazolidinone antibiotic, is safe and effective in the treatment of mild to moderate community acquired pneumonia (CAP).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Radezolid | 300 mg/day, orally for 7-10 days |
| DRUG | Radezolid | 450 mg/day orally for 7-10 days |
| DRUG | Radezolid | 900 mg/day orally for 7-10 days |
Timeline
- Start date
- 2007-10-01
- Primary completion
- 2009-03-01
- Completion
- 2009-04-01
- First posted
- 2008-03-21
- Last updated
- 2016-05-12
- Results posted
- 2010-02-04
Locations
30 sites across 3 countries: United States, Canada, Russia
Source: ClinicalTrials.gov record NCT00640926. Inclusion in this directory is not an endorsement.